Skip to Main content Skip to Navigation
Master Thesis

Impact budgétaire de l’élimination de l’hépatite C en France : comparaison de 3 stratégies de dépistage et d’accès au traitement

Abstract : Since the arrival of DAAs disrupted the management of hepatitis C, the eradication of this disease has seemed achievable. In 2016, France set the goal of eliminating this disease by 2025 using these new treatments. However, eliminating a disease requires significant financial investments. We sought to assess the effectiveness and budgetary impact of 3 elimination strategies on a French scale using a budget impact model: a reference strategy, based on the situation in 2016-2018; a strategy in which screening is increased by 10%, and a strategy in which screening is sufficient to achieve elimination by 2025. With a time horizon in 2030, budget impact of the reference strategy is €4.8 billion, and that of strategy #2 is €5 billion; none of these strategies allow the achievement of elimination by 2025. Strategy #3 achieves elimination and its budgetary impact is €5.9bn. These results should be discussed as a model is a representation of reality for which there is some uncertainty, moreover, the prices of treatments and tests are likely to vary. A public health program is necessary to achieve elimination and the cost of that program is not included in our analysis.
Document type :
Master Thesis
Complete list of metadata

https://dumas.ccsd.cnrs.fr/dumas-03173909
Contributor : Université Paris Descartes - Scd Connect in order to contact the contributor
Submitted on : Thursday, March 18, 2021 - 5:40:32 PM
Last modification on : Friday, September 3, 2021 - 3:32:56 AM

File

ThExe_NAJEAN _Marie _DUMAS.pdf
Files produced by the author(s)

Licence


Distributed under a Creative Commons Attribution - NonCommercial - NoDerivatives 4.0 International License

Identifiers

  • HAL Id : dumas-03173909, version 1

Citation

Marie Najean. Impact budgétaire de l’élimination de l’hépatite C en France : comparaison de 3 stratégies de dépistage et d’accès au traitement. Médecine humaine et pathologie. 2019. ⟨dumas-03173909⟩

Share

Metrics

Record views

8

Files downloads

7